Currently, a phase 2 trial (NCT04475016) is investigating the use of neoadjuvant TIP + nimotuzumab (epidermal growth factor receptor [EGFR] mAb) + triprilimab (anti-PD-1) in patients with locally advanced PSCC (cT4Nany or cTanyN3) [155]. Here, EGFR is linked to squamous cell carcinoma of penis.